Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2

Proc Natl Acad Sci U S A. 1988 Nov;85(21):8037-41. doi: 10.1073/pnas.85.21.8037.

Abstract

Recombinant human interferon-beta 2 was produced in Escherichia coli by direct expression of cDNA encoding the mature protein sequence. At concentrations that stimulate DNA synthesis and growth in B-cell hybridomas and plasmacytomas, the cytokine was found to exert a strong inhibition on the growth of a number of carcinoma and leukemia/lymphoma cell lines. This antigrowth effect was observed in clonogenic assays and by measurements of cell number and thymidine incorporation in growing cultures. The effect was blocked by antibodies to a synthetic peptide from the N terminus of the molecule. Normal diploid fibroblasts were inhibited at concentrations higher than those needed for breast carcinoma cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / pathology*
  • Cell Division / drug effects
  • Cell Line
  • DNA / metabolism
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Humans
  • Interferon Type I / pharmacology*
  • Leukemia / pathology*
  • Lymphoma / pathology*
  • Recombinant Proteins / pharmacology

Substances

  • Interferon Type I
  • Recombinant Proteins
  • DNA